Dataset Information

Survival outcomes of breast cancer patients with brain metastases: A multicenter retrospective study in Korea (KROG 16-12).

ABSTRACT: PURPOSE:This study evaluated the influence of prognostic factors and whole brain radiotherapy (WBRT) on overall survival (OS) of breast cancer (BC) patients with brain metastases (BM). METHODS AND MATERIALS:Medical records of 730 BC patients diagnosed with BM from 2000 to 2014?at 17 institutions were retrospectively reviewed. OS was calculated from BM diagnosis. Median follow-up duration was 11.9 months (range, 0.1-126.2). RESULTS:Median OS was 15.0 months (95% CI: 14.0-16.9). Patients with different BC-specific graded prognostic assessment (GPA) scores showed significant differences (p?4; p?=?0.002), hormone receptor negativity (p?=?0.005), HER2-negativity (p?=?0.003), and shorter time interval (<30 months) between BC and BM diagnosis (p?=?0.007) were associated with inferior OS. By summing the ?-coefficients of variables that were prognostic in multivariate analyses, we developed a prognostic model that stratified patients into low-risk (?0.673) and high-risk (>0.673) subgroups; the high-risk subgroup had poorer median OS (10.1 months, 95% CI: 7.9-11.9 vs. 21.9 months, 95% CI: 19.5-27.1, p?

SUBMITTER: Kim JS

PROVIDER: S-EPMC7375558 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Survival outcomes of breast cancer patients with brain metastases: A multicenter retrospective study in Korea (KROG 16-12).

Kim Jae Sik JS Kim Kyubo K Jung Wonguen W Shin Kyung Hwan KH Im Seock-Ah SA Kim Hee-Jun HJ Kim Yong Bae YB Chang Jee Suk JS Choi Doo Ho DH Park Yeon Hee YH Kim Dae Yong DY Kim Tae Hyun TH Choi Byung Ock BO Lee Sea-Won SW Kim Suzy S Kwon Jeanny J Kang Ki Mun KM Chung Woong-Ki WK Kim Kyung Su KS Nam Ji Ho JH Yoon Won Sup WS Kim Jin Hee JH Cha Jihye J Oh Yoon Kyeong YK Kim In Ah IA

Breast (Edinburgh, Scotland) 20191022

<h4>Purpose</h4>This study evaluated the influence of prognostic factors and whole brain radiotherapy (WBRT) on overall survival (OS) of breast cancer (BC) patients with brain metastases (BM).<h4>Methods and materials</h4>Medical records of 730 BC patients diagnosed with BM from 2000 to 2014 at 17 institutions were retrospectively reviewed. OS was calculated from BM diagnosis. Median follow-up duration was 11.9 months (range, 0.1-126.2).<h4>Results</h4>Median OS was 15.0 months (95% CI: 14.0-16. ...[more]

PMID: 31677532

Similar Datasets

Project description:BackgroundBrain metastases (BM) occur frequently in patients with metastatic kidney cancer and are a significant source of morbidity and mortality. Although historically associated with a poor prognosis, survival outcomes for patients in the modern era are incompletely characterized. In particular, outcomes after adjusting for systemic therapy administration and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk factors are not well-known.Patients and methodsA retrospective database of patients with metastatic renal cell carcinoma (RCC) treated at University of Texas Southwestern Medical Center between 2006 and 2015 was created. Data relevant to their diagnosis, treatment course, and outcomes were systematically collected. Survival was analyzed by the Kaplan-Meier method. Patients with BM were compared with patients without BM after adjusting for the timing of BM diagnosis, either prior to or during first-line systemic therapy. The impact of stratification according to IMDC risk group was assessed.ResultsA total of 56 (28.4%) of 268 patients with metastatic RCC were diagnosed with BM prior to or during first-line systemic therapy. Median overall survival (OS) for systemic therapy-naive patients with BM compared with matched patients without BM was 19.5 versus 28.7 months (P = .0117). When analyzed according to IMDC risk group, the median OS for patients with BM was similar for favorable- and intermediate-risk patients (not reached vs. not reached; and 29.0 vs. 36.7 months; P = .5254), and inferior for poor-risk patients (3.5 vs. 9.4 months; P = .0462). For patients developing BM while on first-line systemic therapy, survival from the time of progression did not significantly differ by presence or absence of BM (11.8 vs. 17.8 months; P = .6658).ConclusionsSurvival rates for patients with BM are significantly better than historical reports. After adjusting for systemic therapy, the survival rates of patients with BM in favorable- and intermediate-risk groups were remarkably better than expected and not statistically different from patients without BM, though this represents a single institution experience, and numbers are modest.

Dataset Information

Survival outcomes of breast cancer patients with brain metastases: A multicenter retrospective study in Korea (KROG 16-12).

Publications

Survival outcomes of breast cancer patients with brain metastases: A multicenter retrospective study in Korea (KROG 16-12).

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets